No End In Sight In Plavix Battle

Law360, New York (August 21, 2006, 12:00 AM EDT) -- Attorneys spent a second day in court Monday arguing over whether Apotex’ generic version of the blockbuster blood thinner Plavix should be allowed on the market.

Sanofi-Aventis, the distributor of Plavix in Europe, and Bristol-Myers Squibb Co., which sells the drug in the United States, are seeking a preliminary injunction against the manufacturing and sale of the generic version of the drug.

Friday, attorneys for Bristol-Myers focused on whether the Apotex generic infringes a basic patent on Plavix that does not expire for at least another...
To view the full article, register now.